At this time, the development of therapeutics for COVID-19 is the overarching goal of the scientific community, and owing to the ultimate role of the S protein in the pathogenesis of the COVID-19 virus, especially the S1 region, designing therapeutics that target its RBD domain is necessary [23]. Here, PROS1 is linked to COVID-19.